Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Etoposide
Drug ID BADD_D00854
Description A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Indications and Usage For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
Marketing Status approved
ATC Code L01CB01
DrugBank ID DB00773
KEGG ID D00125
MeSH ID D005047
PubChem ID 36462
TTD Drug ID D0B7EB
NDC Product Code 0378-3266; 0143-9510; 63323-104; 55361-0006; 68001-265; 0703-5656; 0143-9512; 16729-114; 0143-9511; 53183-8538; 57884-0008; 53104-7514; 0143-9376
UNII 6PLQ3CP4P3
Synonyms Etoposide | Eposide | Demethyl Epipodophyllotoxin Ethylidine Glucoside | Eto-GRY | Eto GRY | Etoposide, (5a alpha,9 alpha)-Isomer | Etoposide, (5S)-Isomer | Etoposide, alpha-D-Glucopyranosyl Isomer | Etoposide, alpha D Glucopyranosyl Isomer | alpha-D-Glucopyranosyl Isomer Etoposide | Etoposido Ferrer Farma | Exitop | Lastet | NSC-141540 | NSC 141540 | NSC141540 | Onkoposid | Riboposid | Toposar | Etoposide Teva | Teva, Etoposide | Vepesid | VP 16-213 | VP 16 213 | VP 16213 | VP-16 | VP 16 | VP16 | Vépéside-Sandoz | Vépéside Sandoz | Celltop | Etopos | Etomedac | Eposin | Etoposide, (5a alpha)-Isomer | Etoposide Pierre Fabre
Chemical Information
Molecular Formula C29H32O13
CAS Registry Number 33419-42-0
SMILES CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC) O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Capillary leak syndrome08.01.07.012; 24.06.03.0010.000112%
Cardiac arrest02.03.04.0010.000504%
Cardiac failure02.05.01.0010.000448%
Cardiac failure congestive02.05.01.002---
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000224%-
Cardiovascular disorder02.11.01.010; 24.03.02.009---
Cellulitis11.02.01.001; 23.11.02.004---
Cerebrospinal fluid leakage12.01.10.004; 17.02.05.0010.000112%
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.0020.002104%-
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.0030.001578%-
Chills08.01.09.001; 15.05.03.0160.001455%
Choking sensation19.01.02.002; 22.12.03.0040.000168%-
Cholestasis09.01.01.0010.000112%-
Circulatory collapse24.06.02.0010.000168%-
Colitis07.08.01.0010.000280%
Coma17.02.09.0010.000392%-
Compartment syndrome15.05.05.005; 24.04.05.0060.000168%-
Confusional state17.02.03.005; 19.13.01.0010.000616%
Constipation07.02.02.001--
Cough22.02.03.0010.003033%
Crying08.01.03.005; 12.02.11.001; 17.02.05.013; 19.04.02.0020.000112%-
Cyanosis02.11.04.004; 22.02.02.007; 23.06.04.005; 24.03.01.0070.000728%
Cystitis haemorrhagic20.03.02.0030.000280%-
Death08.04.01.001--
Dermatitis23.03.04.002---
Diarrhoea07.02.01.001--
Discomfort08.01.08.0030.000112%-
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000280%
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug hypersensitivity10.01.01.001---
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene